Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Dologen, Dologesic
Synonyms :
dexbrompheniramine
Class :
Antihistamines and Antiallergics
Brand Name :
Dologen, Dologesic
Synonyms :
dexbrompheniramine
Class :
Antihistamines and Antiallergics
Dosage Forms & StrengthsÂ
Tablet Â
1 mgÂ
2 mg Â
Take a dose of 2 mg in combination with pseudoephedrine up to four times a day
Dosage Forms & StrengthsÂ
Tablet Â
1 mgÂ
2 mg Â
For >6 years old:
Take a dose of 1 mg in combination with pseudoephedrine up to four times a day
Refer to adult dosingÂ
CNS stimulants: they may increase the CNS depressant effect of antihistamines
CNS stimulants: they may increase the CNS depressant effect of antihistamines
CNS stimulants: they may increase the CNS depressant effect of antihistamines
The Therapeutic efficacy of pitolisant may be reduced by antihistamines
tiotropium: they may decrease the therapeutic effect of antihistamines
it may enhance the risk of cns depression when combined with aripiprazole lauroxil
The potential for increased CNS depression risk or seriousness occurs when dexbrompheniramine is used together with pinazepam
when ajmaline is used together with dexbrompheniramine, the risk or seriousness of QTc prolongation is enhanced
The potential for increased CNS depression risk or seriousness occurs when dexbrompheniramine is used together with pipecuronium
When dexbrompheniramine is used together with medazepam, the risk or seriousness of CNS depression is enhanced
When dexbrompheniramine is used together with niaprazine, the risk or seriousness of CNS depression is enhanced
When dexbrompheniramine is used together with levosulpiride, the risk or seriousness of CNS depression is enhanced
When chlordiazepoxide is used together with dexbrompheniramine, this leads to enhanced risk or seriousness of CNS depression
When dexbrompheniramine is used together with melitracen, this leads to enhanced risk or seriousness of CNS depression
When ponesimod is used together with dexbrompheniramine, this leads to enhanced risk or seriousness of bradycardia
When dexbrompheniramine is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
When dexbrompheniramine is used together with givinostat, this leads to enhanced risk or seriousness of Qtc prolongation
When emylcamate is used together with dexbrompheniramine, this leads to enhanced risk or seriousness of CNS depression
When acepromazine is used together with dexbrompheniramine, this leads to enhanced risk or seriousness of CNS depression
hyaluronidase: they may decrease the therapeutic effect of antihistamines
betahistine's therapeutic efficacy may be reduced by antihistamines
Itopride therapeutic efficacy may be reduced by antihistamines
sodium hyaluronate: they may diminish the therapeutic effect of antihistamines
It may enhance the risk of adverse effects when combined with platelet Inhibitors
It may enhance the risk of adverse effects when combined with platelet Inhibitors
It may enhance the risk of adverse effects when combined with platelet Inhibitors
It may enhance the risk of adverse effects when combined with platelet Inhibitors
It may enhance the risk of adverse effects when combined with platelet Inhibitors
Actions and SpectrumÂ
dexbrompheniramine is an H1 receptor antagonist. It competes with histamine for binding to H1 receptors on target cells in the body. dexbrompheniramine blocks the actions of histamine, preventing or alleviating the symptoms of an allergic reaction.
Frequency not defined Â
SeizureÂ
DrowsinessÂ
Dry mouth, noseÂ
Constipation Â
Easy bruising or bleedingÂ
Unusual weaknessÂ
Feeling short of breathÂ
Fast or uneven heart rateÂ
Mood changesÂ
TremorÂ
Black Box WarningÂ
NoneÂ
Contraindication/Caution:Â
Contraindication:Â
Caution:Â
Pregnancy consideration:Â
Pregnancy category: CÂ
Lactation: Excretion into human milk is unknown Â
Pregnancy Categories:        Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.Â
Category N: There is no data available for the drug under this category.Â
Pharmacology Â
dexbrompheniramine is an H1 histamine receptor antagonist. It competes with histamine for binding to H1 receptors found on various cells throughout the body, including those in the respiratory tract, blood vessels, and skin.Â
PharmacodynamicsÂ
dexbrompheniramine counteract the effects of histamine release in response to allergens. It reduces or alleviates the symptoms of allergic reactions, such as those associated with hay fever and allergic conjunctivitis.Â
PharmacokineticsÂ
Absorption  Â
dexbrompheniramine is well-absorbed from the gastrointestinal tract when taken orally. Â
DistributionÂ
dexbrompheniramine is distributed throughout the body.Â
MetabolismÂ
dexbrompheniramine is metabolized in the liver.Â
Elimination and excretionÂ
dexbrompheniramine is excreted through the kidneys in the urine.Â
AdministrationÂ
dexbrompheniramine is taken orally and is available in tablet form.Â
Patient information leafletÂ
Generic Name: dexbrompheniramineÂ
Why do we use dexbrompheniramine?Â
dexbrompheniramine used to provide relief from allergy-related symptoms. Â
dexbrompheniramine is used to reduce itching and redness of the eyes associated with allergic conjunctivitis.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
